PrEP has little to no direct toxicity to the liver. The main medication used in oral PrEP, tenofovir, has been extensively studied, and liver safety data from clinical trials and real-world use consistently show that serious liver problems are rare in otherwise healthy people. That said, there are specific situations where PrEP and liver health intersect in important ways, particularly if you have hepatitis B or use PrEP for many years.
What PrEP Does (and Doesn’t Do) to Your Liver
Tenofovir, the backbone of both Truvada and Descovy, is classified by the National Institute of Diabetes and Digestive and Kidney Diseases as having “little or no direct hepatotoxicity.” Once you swallow the pill, it’s absorbed in the intestines and converted inside your cells into its active form, which blocks HIV from copying itself. Unlike some older antiviral drugs, tenofovir doesn’t significantly interfere with the energy-producing structures inside liver cells, a process called mitochondrial toxicity that was responsible for liver failure seen with earlier HIV medications.
Some of the alarming case reports linking tenofovir to liver failure actually involved patients who were simultaneously taking older drugs like didanosine or stavudine. Tenofovir can raise the levels of didanosine in the body by up to 60%, amplifying that drug’s potential for mitochondrial damage. These older drugs are not part of PrEP regimens and are rarely used today.
Liver Enzyme Changes During PrEP Use
Mild elevations in liver enzymes (the blood markers that signal liver stress) do occur in some people on PrEP, but they happen at roughly the same rate regardless of which PrEP formulation you take. In the large HPTN 083 trial, which compared injectable cabotegravir (Apretude) to daily oral tenofovir-based PrEP, both groups showed nearly identical rates of elevated liver enzymes: about 5 per 100 person-years for one marker and about 4 per 100 person-years for the other. This suggests the elevations aren’t strongly tied to tenofovir itself and may reflect normal background variation, alcohol use, or other factors.
Most of these enzyme bumps are mild and temporary. They don’t cause symptoms and often resolve on their own without stopping the medication.
The Hepatitis B Connection
The most significant liver risk with PrEP isn’t from taking it. It’s from stopping it, if you have hepatitis B. Tenofovir and emtricitabine (the two drugs in Truvada and Descovy) both actively suppress hepatitis B virus replication. If you have chronic hepatitis B and you stop PrEP, the virus can rebound aggressively, triggering a flare of liver inflammation that in rare cases can lead to acute liver failure.
This is why the CDC requires hepatitis B screening before prescribing oral PrEP. Having hepatitis B is not a reason to avoid PrEP. In fact, PrEP can help control the infection while you’re taking it. But you need to know your status before starting, and if you decide to stop PrEP, your liver function should be closely monitored for signs of viral rebound. Some clinicians remain cautious about prescribing PrEP to people with chronic hepatitis B precisely because the consequences of inconsistent use or sudden discontinuation are not fully quantified in PrEP-specific studies.
Long-Term Use and Liver Risk
One large observational study, known as the D:A:D study, found that five years of cumulative tenofovir use was associated with a 46% increase in the relative risk of serious liver disease, including end-stage liver disease and liver cancer. That sounds alarming, but context matters significantly here.
The D:A:D study followed people living with HIV who were on multi-drug antiretroviral therapy, not healthy individuals using PrEP. Many participants had hepatitis B or C coinfection, long histories of other antiretroviral medications, and HIV-related immune damage, all of which independently raise liver disease risk. A 46% relative increase on top of a small baseline risk still translates to a small absolute risk. Whether this finding applies to otherwise healthy PrEP users taking a simpler two-drug regimen is genuinely uncertain, but it’s the closest thing to long-term data available and a reasonable basis for ongoing monitoring.
Signs of Liver Problems to Watch For
Drug-induced liver injury from any medication can produce a recognizable set of symptoms. While these are uncommon with PrEP, knowing what to look for is worthwhile:
- Yellowing of the skin or eyes (jaundice), the most specific sign of liver distress
- Dark urine or pale stools, which indicate changes in how your liver processes bile
- Persistent nausea, vomiting, or loss of appetite
- Unexplained fatigue or stomach pain
- New rash, itching, or fever
These symptoms overlap with many other conditions, so their presence doesn’t automatically mean your liver is in trouble. But if you’re on PrEP and notice a combination of these, especially jaundice or dark urine, getting your liver enzymes checked promptly is reasonable.
Who Should Pay Extra Attention
For most healthy people, PrEP’s liver profile is reassuring. But a few groups deserve closer monitoring. If you have chronic hepatitis B, the discontinuation risk described above is real and needs a management plan. If you drink heavily, your liver is already under strain, and adding any daily medication creates a higher baseline for potential problems. If you have pre-existing liver disease from any cause, your prescriber will likely check liver enzymes more frequently during the first year of PrEP and periodically afterward.
Routine PrEP follow-up visits, which typically happen every three months, provide a built-in opportunity to catch any emerging liver issues early, even when you’re feeling fine. The standard monitoring schedule wasn’t designed around liver concerns specifically, but it serves as an effective safety net.